Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Invested Capital (2019 - 2023)

Historic Invested Capital for ADC Therapeutics (ADCT) over the last 4 years, with Q3 2023 value amounting to $55.3 billion.

  • ADC Therapeutics' Invested Capital fell 2019.34% to $55.3 billion in Q3 2023 from the same period last year, while for Sep 2023 it was $55.3 billion, marking a year-over-year decrease of 2019.34%. This contributed to the annual value of $506.3 million for FY2022, which is 32408.12% up from last year.
  • Latest data reveals that ADC Therapeutics reported Invested Capital of $55.3 billion as of Q3 2023, which was down 2019.34% from $58.0 billion recorded in Q2 2023.
  • ADC Therapeutics' Invested Capital's 5-year high stood at $79.9 billion during Q1 2022, with a 5-year trough of $89797.0 in Q3 2021.
  • For the 4-year period, ADC Therapeutics' Invested Capital averaged around $33.2 billion, with its median value being $27.9 billion (2022).
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 8265585267.64% in 2022, then tumbled by 2407.01% in 2023.
  • Quarter analysis of 4 years shows ADC Therapeutics' Invested Capital stood at $23.8 million in 2019, then surged by 401.82% to $119.4 million in 2021, then soared by 324.08% to $506.3 million in 2022, then skyrocketed by 10822.48% to $55.3 billion in 2023.
  • Its Invested Capital was $55.3 billion in Q3 2023, compared to $58.0 billion in Q2 2023 and $60.7 billion in Q1 2023.